Can We Predict Work Disability in Lupus? Save

When it comes to managing patients with systemic lupus erythematosus (SLE) there are many aspects of the disease to consider – disease activity, organs involved, and the potential for long term damage. Given that SLE affects many working-age adults, there is another dimension to consider: work disability.

Despite our increased understanding of lupus immunology including treatment options, many of our patients with SLE continue to experience significant functional impairment and work disability. Several abstracts from ACR 2026 highlight the burden of work disability, the factors associated with employment outcomes, and the potential to identify patients at risk before disability occurs.

Abstract 1299 presents a systematic review and meta-analysis of 44 studies involving nearly 20,000 patients with SLE. The pooled prevalence of work disability was 43% when assessed by employment status. Individual factors associated with work disability included fatigue, pain, cognitive impairment, disease activity, and organ damage. Beyond disease-related factors, inadequate workplace accommodations and high occupational demands were important contributors. 

Abstract 1266 takes a deep dive to evaluate the trajectories of employment in a large cohort of patients with SLE who were followed for almost 18 years. Neuropsychiatric, renal, endocrine, and musculoskeletal organ damage were associated with disability benefit status. Persistent immunological activity also correlated with disability. Neurologic activity among those employed was a predictor for mortality. Given that we understand the risks surrounding disability in patients with lupus, can we identify patients at risk before disability occurs?

Abstract 0925 explored a machine-learning approach to predict work disability using longitudinal clinical data from nearly 1000 employed patients with SLE. The model identified nearly 90% of patients who later developed work disability, including a median warning time of approximately 29 months before the first reported disability event. Important predictors included increasing disease activity, higher glucocorticoid exposure, shorter intervals between visits, and changes in antimalarial treatment. While the model demonstrated positive performance, factors beyond the clinic, including workplace demands, accommodations, and socioeconomic circumstances, may be difficult to capture and may not be fully accounted for.

As our therapeutic options for lupus continue to expand, preventing long-term disability should remain a priority in lupus care. Identifying patients at risk may provide an opportunity for earlier intervention, but disease control alone may not be sufficient. Future efforts should consider factors beyond the clinic, including rehabilitation, workplace accommodations, and social support, to help patients remain in or return to the workforce.